Solventum (NYSE:SOLV) Updates FY 2025 Earnings Guidance

Solventum (NYSE:SOLV) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 5.450-5.650 for the period, compared to the consensus estimate of 5.540. The company issued revenue guidance of -.

Solventum Trading Up 0.8 %

NYSE:SOLV opened at $66.23 on Friday. The firm has a market capitalization of $11.46 billion and a price-to-earnings ratio of 24.08. The business’s 50-day moving average price is $73.41 and its two-hundred day moving average price is $71.64. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. Solventum has a 1-year low of $47.16 and a 1-year high of $85.92.

Wall Street Analysts Forecast Growth

SOLV has been the topic of several recent analyst reports. Wells Fargo & Company lifted their price objective on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a report on Friday, February 28th. Piper Sandler increased their price objective on shares of Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. Bank of America boosted their price objective on shares of Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research report on Wednesday, February 26th. Morgan Stanley upped their target price on shares of Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 5th. Finally, The Goldman Sachs Group lifted their price target on Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a research note on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $79.86.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.